GEM is a pilot study to evaluate the use of semaglutide (Wegovy) for the treatment of methamphetamine use disorder (MeUD).
This pilot study will be an open-label, single-arm pilot study of 25 participants. Participants will receive Wegovy over a 12-week treatment period, with a subsequent follow-up visit at week 20. This phase will evaluate the feasibility, acceptability, and preliminary efficacy of Wegovy for MeUD.